MXPA03002480A - Inmunogeno que comprende ligando enlazado a proteinas de envoltura de vih. - Google Patents

Inmunogeno que comprende ligando enlazado a proteinas de envoltura de vih.

Info

Publication number
MXPA03002480A
MXPA03002480A MXPA03002480A MXPA03002480A MXPA03002480A MX PA03002480 A MXPA03002480 A MX PA03002480A MX PA03002480 A MXPA03002480 A MX PA03002480A MX PA03002480 A MXPA03002480 A MX PA03002480A MX PA03002480 A MXPA03002480 A MX PA03002480A
Authority
MX
Mexico
Prior art keywords
immunogen
envelpe
protein
ligand bound
bound hiv
Prior art date
Application number
MXPA03002480A
Other languages
English (en)
Inventor
Barton F Haynes
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of MXPA03002480A publication Critical patent/MXPA03002480A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere, en general, a un inmunogeno, y en particular, a un inmunogeno para inducir anticuerpos que neutralizan un amplio espectro de aislados primarios de VIH. La invencion tambien se refiere a un metodo para inducir anticuerpos anti-VIH utilizando el mismo.
MXPA03002480A 2000-09-22 2001-09-24 Inmunogeno que comprende ligando enlazado a proteinas de envoltura de vih. MXPA03002480A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23432700P 2000-09-22 2000-09-22
US28517301P 2001-04-23 2001-04-23
US32370201P 2001-09-21 2001-09-21
US32369701P 2001-09-21 2001-09-21
PCT/US2001/029830 WO2002024149A2 (en) 2000-09-22 2001-09-24 Immunogen comprising ligand bound hiv envelpe protein

Publications (1)

Publication Number Publication Date
MXPA03002480A true MXPA03002480A (es) 2004-05-24

Family

ID=27499729

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03002480A MXPA03002480A (es) 2000-09-22 2001-09-24 Inmunogeno que comprende ligando enlazado a proteinas de envoltura de vih.

Country Status (11)

Country Link
US (2) US7101552B2 (es)
EP (1) EP1331942A4 (es)
JP (1) JP2004511444A (es)
KR (1) KR20030036819A (es)
CN (1) CN1505528A (es)
AU (2) AU9466701A (es)
BR (1) BR0114094A (es)
CA (1) CA2423127A1 (es)
IL (1) IL154991A0 (es)
MX (1) MXPA03002480A (es)
WO (1) WO2002024149A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0108210A (pt) 2000-02-04 2002-10-22 Univ Duke Vacina contra o vìrus da imunodeficiência humana
IL154991A0 (en) 2000-09-22 2003-10-31 Univ Duke Immunogen comprising ligand bound hiv envelope protein
US20080213296A1 (en) * 2000-09-22 2008-09-04 Duke University Immunogen
US7033593B2 (en) * 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
ATE481109T1 (de) * 2001-10-16 2010-10-15 Us Gov Health & Human Serv Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden
CA2466050A1 (en) 2001-11-07 2003-05-15 Duke University Polyvalent immunogen
US7172761B2 (en) * 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
EP1554392A4 (en) * 2002-05-06 2007-08-08 Us Gov Health & Human Serv IDENTIFICATION OF WIDE-NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES WITH CROSS-REACTION USING SEQUENTIAL PLATE ADHESION METHOD OF ANTIGENS OF PHAGE PRESENTATION BANKS
EP1504034B1 (en) * 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
WO2004009785A2 (en) 2002-07-23 2004-01-29 Duke University IgG Fc/HIV-gp120/C3d FUSION PROTEIN
US7074238B2 (en) 2003-07-08 2006-07-11 Archus Orthopedics, Inc. Prostheses, tools and methods for replacement of natural facet joints with artificial facet joint surfaces
CA2539325C (en) 2003-09-17 2016-03-22 Duke University Consensus/ancestral immunogens
US20050249428A1 (en) * 2004-05-07 2005-11-10 Ming-Jun Chen Method of weeding out repeating patterns from programs
CA2576636A1 (en) 2004-08-18 2006-03-02 Archus Orthopedics, Inc. Adjacent level facet arthroplasty devices, spine stabilization systems, and methods
US20080038280A1 (en) * 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
CA2585574A1 (en) * 2004-10-29 2006-05-11 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5019387A (en) 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
US5993819A (en) 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
US5516632A (en) 1988-02-08 1996-05-14 Duke University Synthetic peptides
US5217473A (en) * 1989-12-05 1993-06-08 Inbae Yoon Multi-functional instruments and stretchable ligating and occluding devices
AU679439B2 (en) 1992-02-10 1997-07-03 Duke University Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens
JPH08506012A (ja) * 1992-12-31 1996-07-02 ラモツト・ユニバーシテイ・オーソリテイ・フオー・アプライド・リサーチ・アンド・インダストリアル・デベロツプメント・リミテツド 結合・連動性エピトープに対する抗体
ATE207760T1 (de) 1993-05-07 2001-11-15 Akzo Nobel Nv Hiv immunogene komplexe
DE69527708T2 (de) 1994-04-29 2003-04-30 Univ Durham Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
EP0868196A4 (en) 1995-10-20 2004-11-24 Univ Duke SYNTHETIC VACCINE TO PROTECT AGAINST INFECTION BY THE HUMANE IMMUNDEFIZIENZ VIRUS
IL141211A0 (en) * 1998-08-03 2002-02-10 Univ Montana Prevention and treatment of viral disease
BR0108210A (pt) 2000-02-04 2002-10-22 Univ Duke Vacina contra o vìrus da imunodeficiência humana
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
IL154991A0 (en) 2000-09-22 2003-10-31 Univ Duke Immunogen comprising ligand bound hiv envelope protein
CA2466050A1 (en) 2001-11-07 2003-05-15 Duke University Polyvalent immunogen
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
US7195768B2 (en) 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
AU2002365576A1 (en) 2001-11-27 2003-06-10 Duke University Hiv envelope v3-ccr5 binding site immunogen
WO2004009785A2 (en) 2002-07-23 2004-01-29 Duke University IgG Fc/HIV-gp120/C3d FUSION PROTEIN
US20080181906A1 (en) 2003-05-19 2008-07-31 Haynes Barton F Polyvalent Immunogen
CA2539325C (en) 2003-09-17 2016-03-22 Duke University Consensus/ancestral immunogens

Also Published As

Publication number Publication date
US7070787B2 (en) 2006-07-04
US20020086283A1 (en) 2002-07-04
CA2423127A1 (en) 2002-03-28
AU9466701A (en) 2002-04-02
EP1331942A2 (en) 2003-08-06
CN1505528A (zh) 2004-06-16
KR20030036819A (ko) 2003-05-09
US7101552B2 (en) 2006-09-05
EP1331942A4 (en) 2005-03-16
WO2002024149A2 (en) 2002-03-28
WO2002024149A3 (en) 2002-09-06
US20040039172A1 (en) 2004-02-26
BR0114094A (pt) 2003-07-22
AU2001294667B2 (en) 2006-08-17
IL154991A0 (en) 2003-10-31
JP2004511444A (ja) 2004-04-15

Similar Documents

Publication Publication Date Title
MXPA03002480A (es) Inmunogeno que comprende ligando enlazado a proteinas de envoltura de vih.
WO2003039470A3 (en) Polyvalent immunogen of hiv
TW200517121A (en) Immunogen
WO2004075850A3 (en) Polyvalent immunogen
AU3117201A (en) Methods and compositions for generating human monoclonal antibodies
MXPA04001224A (es) Agentes para incrementar la respuesta inmune.
DE69435126D1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
GEP20105118B (en) Anti-vegf antibodies
WO2005028625A3 (en) Consensus/ancestral immunogens
DE69332744T2 (de) Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
AU2002224893A1 (en) Method for producing a part and device for carrying out this method
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
BR0209242A (pt) Aminopolidiorganossiloxanos amido-funcionais
SE9704546D0 (sv) Novel compounds
AP1703A (en) Heparin-derived polysaccharide mixtures, preparation method and pharmaceutical compositions containing same.
SI1572087T1 (sl) Protitelesa proti antigenu tmeff2 raka in njihovauporaba
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2004009785A3 (en) IgG Fc/HIV-gp120/C3d FUSION PROTEIN
EP1585477A4 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
WO2003046137A3 (en) Hiv envelope v3-ccr5 binding site immunogen
AU1817902A (en) Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)
WO2003050137A3 (en) Toll-like receptor 4 mutations
AU2002217212A1 (en) Method for preparing a human monoclonal antibody, fragments thereof or antibodies comprising such fragments, resulting antibodies and use thereof
WO2005016952A3 (en) Polyvalent immunogen
MXPA04002103A (es) Una proteina de union a caspasa-8, su preparacion y uso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal